[1]Soomro QH, Charytan DM. Cardiovascular autonomic nervous system dysfunction in chronic kidney disease and end-stage kidney disease: disruption of the complementary forces[J]. Curr Opin Nephrol Hypertens, 2021, 30(2):198-207.[2]Mcglinchey RP, Lacy SM, Walker RL, et al. Cathepsin K is a potent disaggregase of α-synuclein fibrils[J]. Biochem Biophys Res Commun, 2020, 529(4):1106-1111.[3]Yue XL, Jiang HY, Xu Y, et al. Cathepsin K deficiency impaired ischemia-induced neovascularization in aged mice[J]. Stem Cells Int, 2020, 6938620.[4]Koldkj?r SAS, Harsl?f T, Langdahl B. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis[J]. Osteoporos Int, 2019, 30(5):995-1002.[5]袁琳, 类延娜, 李玉子, 等. 组织蛋白酶K、胱抑素C与冠心病及其危险因素的相关性[J]. 中国老年学, 2015, 35(23):6725-6727.[6]Izumi Y,?Hayashi M,?Morimoto R, et al. Impact of circulating cathepsin K on the coronary calcification and the clinical outcome in chronic kidney disease patients[J]. Heart Vessels, 2016, 31(1):6-14.[7]Binkley N, Orwoll E, Chapurlat R, et al. Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis[J]. Osteoporos Int, 2021, 32(1):173-184.[8]Yuan XY, Ren Z, Wu Y, et al. Design, synthesis and biological evaluation of inhibitors of cathepsin K on dedifferentiated chondrocytes[J]. Bioorg Med Chem, 2019, 27(6):1034-1042.[9]王丹, 王治洁. 血清β-胶原降解产物、组织蛋白酶K和骨保护素对绝经后骨质疏松患者诊断的研究[J]. 中国骨质疏松杂志, 2019, 25(9):1231-1235.[10]Bolignano D, Greco M, Arcidiacono V, et al. Increased circulating Cathepsin-K levels reflect PTH control in chronic hemodialysis patients[J]. J Nephrol, 2021, 34(2):451-458[11]Carrillo-López N, Panizo S, Alonso-Montes C, et al. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease[J]. Kidney Int, 2016, 90(1):77-89.[12]Hao L, Zhu GC, Lu Y, et al. Deficiency of cathepsin K prevents inflammation and bone erosion in rheumatoid arthritis and periodontitis and reveals its shared osteoimmune role[J]. FEBS Lett, 2015, 589(12):1331-1339.[13]Bolignano D, Greco M, Arcidiacono V, et al. Cathepsin-K is a potential cardiovascular risk biomarker in prevalent hemodialysis patients[J]. Int Urol Nephrol, 2021, 53(1):171-175.[14]赵宇, 方正旭, 李丽莎, 等. 组织蛋白酶K、脂蛋白相关磷脂酶A2、缺血修饰白蛋白以及和肽素等因子与冠心病的关系综述[J]. 中国医学创新, 2019, 16(16):169-172.[15]曾淑敏, 谭华清, 唐湘宇, 等. 血清组织蛋白酶K及胱抑素C水平与急性冠脉综合征的关系[J]. 现代实用医学, 2020, 32(12):1461-1463.[16]郑婧, 林燕珊, 张健, 等. 老年人血清组织蛋白酶K与冠心病的相关性研究[J]. 实用老年医学, 2019, 33(10):1000-1003.[17]Izumi Y, Hayashi M, Morimoto R, et al, Impact of circulating cathepsin K on the coronary cal-cification and the clinical outcome in chronic kidney disease patients[J]. Heart Vessels, 2016, 31(1):6-14. |